Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). An open label multicenter randomized phase II study. A study of the Dutch Head and Neck Cancer Group (DHNCG) (NWHHT 08-02).

Trial Profile

Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). An open label multicenter randomized phase II study. A study of the Dutch Head and Neck Cancer Group (DHNCG) (NWHHT 08-02).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2014

At a glance

  • Drugs Docetaxel (Primary) ; Lapatinib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms TyvTax study
  • Most Recent Events

    • 29 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top